Illumina (ILMN) Projected to Announce Quarterly Earnings on Thursday

Illumina (NASDAQ:ILMN) is expected to announce its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $1.36 per share and revenue of $1.15 billion for the quarter. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.19 EPS. On average, analysts expect Illumina to post $5.36 EPS for the current fiscal year and $6.12 EPS for the next fiscal year.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $271.04 on Tuesday. The firm has a fifty day moving average price of $241.80 and a 200-day moving average price of $173.01. Illumina has a 1 year low of $94.00 and a 1 year high of $309.35. The stock has a market cap of $40.93 billion, a PE ratio of 52.31, a price-to-earnings-growth ratio of 3.82 and a beta of 1.41. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of research reports. Royal Bank Of Canada upped their target price on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Stephens reaffirmed an “equal weight” rating and set a $275.00 price target on shares of Illumina in a research note on Friday. Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. TD Cowen upped their price objective on Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a research note on Tuesday, October 13th. Finally, Canaccord Genuity Group increased their target price on shares of Illumina from $205.00 to $300.00 and gave the company a “hold” rating in a research report on Monday, October 19th. Ten investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and an average target price of $234.41.

Insiders Place Their Bets

In related news, Director Keith Meister sold 457,858 shares of the stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders have sold 2,061,850 shares of company stock valued at $436,479,102. 2.90% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.